Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer

This publication has 17 references indexed in Scilit:

• Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1995
• Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.
  1993
• CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
  Journal of Clinical Oncology, 1992
• Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
  New England Journal of Medicine, 1992
• A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
  Journal of Clinical Oncology, 1992
• DNA Damaging and Cell Cycle Effects of the Topoisomerase I Poison Camptothecin in Irradiated Human Cells
  International Journal of Radiation Biology, 1992
• Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1991
• A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
  New England Journal of Medicine, 1990
• INHIBITION OF POTENTIALLY LETHAL DNA DAMAGE REPAIR IN HUMAN-TUMOR CELLS BY BETA-LAPACHONE, AN ACTIVATOR OF TOPOISOMERASE-I
  1989